• LSE Platforms for Spatiotemporal mRNA Delivery

  2026-08-25

  The reference study develops a lipid nanoparticle-stabilized emulsion (LSE) that redirects mRNA delivery toward antigen-presenting cells and improves the durability and breadth of T cell responses in mice. Its findings suggest that controlling where and when antigen is expressed may be as important as increasing total mRNA expression, although translation beyond preclinical models remains unresolved.

• Thioredoxin 1 and Lens Iron Metabolism in Oxidative Damage

  2026-08-24

  This preprint identifies thioredoxin 1 (Trx1) as a possible regulator of late-stage recovery from oxidative damage and iron dysregulation in the lens, with ferritin heavy chain (FTH1) implicated as a downstream mediator. Its staged in vivo and in vitro design emphasizes that age-related cataract biology may change over time, although the proposed Trx1–FTH1 mechanism requires validation in peer-reviewed and clinically relevant models.

• Rifampin Workflows for Bacterial Transcription Studies

  2026-08-23

  Rifampin provides a practical, mechanistically defined way to interrupt bacterial transcription for RNA turnover, promoter-dynamics, and resistance experiments. This guide connects stock preparation and time-course design with lessons from light-controlled translational regulation, while keeping bacterial and mammalian assay interpretations distinct.

• Carbapenemase Gene Transfer in CREC Across Guangdong

  2026-08-22

  This multicenter study integrates carbapenemase-gene localization, antimicrobial susceptibility testing, conjugation assays, mobile-element analysis, and strain genotyping to clarify how carbapenem-resistant Enterobacter cloacae disseminates across teaching hospitals. Its findings emphasize the epidemiological importance of plasmid-borne blaNDM-1, efficient horizontal transfer, and multidrug resistance for infection-control and Gram-negative bacterial infection research.

• High Viscosity Drives P-gp Chemoresistance

  2026-08-21

  The 2026 reference study identifies extracellular fluid viscosity as a mechanical regulator of doxorubicin resistance, linking cell swelling and membrane tension to TRPV4, YAP, and P-gp signaling. Its main contribution is to show that tumor-fluid rheology can influence drug resistance through a defined mechanotransduction pathway, while also highlighting viscosity reduction as a testable strategy that requires further validation.

• EdU Flow Cytometry Assay Kits (Cy5): Practical Guide

  2026-08-20

  EdU Flow Cytometry Assay Kits (Cy5) provide a practical way to measure DNA synthesis in S-phase cells using click chemistry and Cy5 fluorescence. This guide covers assay setup, controls, and troubleshooting; the method should not be interpreted as a standalone measure of total cell number, completed cell division, or viability.

• Angiotensin I/II (1-5) Protocol Guide

  2026-08-20

  Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for controlled renin-angiotensin system research, including cardiovascular, renal, blood pressure, and aldosterone-related workflows. It should not be treated as a general peptide-signaling reagent or used outside relevant RAS experiments without separate validation of biological relevance, solubility, and assay compatibility.

• Y-27632 for Reliable Cell Assays

  2026-08-19

  Learn how Y-27632 (SKU B1293) can help researchers separate ROCK-dependent cytoskeletal effects from genuine changes in cell viability, proliferation, and cytotoxicity. This scenario-based guide covers assay compatibility, dose selection, interpretation, storage, and practical vendor evaluation.

• Nullscript: HDAC Inhibitor Workflows for I/R

  2026-08-19

  Nullscript is a histone deacetylase inhibitor designed for mechanistic studies that separate HDAC inhibition from transcriptional facilitation. This guide connects its cardiac ischemia/reperfusion use case with rigorous cell-based workflows, pathway-focused controls, and assay troubleshooting without overstating evidence from exploratory neurodegenerative, cancer, or renal models.

• HyperScribe Co-transcription mRNA Synthesis Kit Plus

  2026-08-18

  The HyperScribe Co-transcription mRNA Synthesis Kit Plus combines T7 transcription, ARCA capping, and template-encoded poly(A) tailing in a practical workflow for translation-ready research RNA. Its strongest use cases range from in vitro translation assays to experimental RNA vaccine development, including construct concepts inspired by recent HCC nanovaccine research.

• PBA-Modified PAD4 Inhibitors Suppress Tumor NETs

  2026-08-18

  The reference study developed meta-phenylboronic acid-modified PAD4 inhibitors that exploit tumor-associated sialic acids while targeting the PAD4–H3cit–NET axis. Compound 5i reduced tumor growth, migration, and lung metastasis in mouse models, supporting tumor-directed PAD4 inhibition as a strategy for studying neutrophil-driven cancer biology with potentially improved tolerability.

• Melatonin, RIPK3, and Atrazine Kidney Necroptosis

  2026-08-17

  The reference study identifies RIPK3-dependent necroptosis as a central mechanism in atrazine-induced kidney injury and shows that melatonin reduces this damage in cellular and animal models. Its combination of pathway analysis, RIPK3 knockdown, and computational binding studies provides a mechanistic framework for investigating chemical nephrotoxicity beyond nonspecific oxidative stress.

• Tofacitinib in RA Macrophage Assays

  2026-08-17

  Tofacitinib (CP-690550) offers a practical way to connect JAK/STAT inhibition with inflammatory phenotype and mitochondrial readouts in GM-CSF-conditioned macrophages. This workflow uses dose-ranging, pathway controls, and orthogonal metabolic assays to distinguish cytokine signaling blockade from nonspecific cytotoxicity.

• NF449 and Platelet P2 Receptor Inhibition

  2026-08-16

  Hechler and colleagues established NF449 as a preferential antagonist of platelet P2X1 receptors and connected receptor-selective blockade with reduced platelet aggregation and thrombus formation. The study also showed that dose determines selectivity in vivo, providing a useful framework for interpreting purinergic platelet assays and antithrombotic strategies.

• Patient-Derived Gastric Cancer Assembloids Explained

  2026-08-15

  Shapira-Netanelov and colleagues developed gastric cancer assembloids that combine patient-matched tumor organoids with stromal subpopulations, providing a more physiologically relevant model of tumor heterogeneity and microenvironmental signaling. Their findings show that stromal composition can reshape gene expression and drug sensitivity, supporting more informative resistance studies and personalized treatment screening.

453 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page